Research programme: anti-proliferative therapeutics - DiscoveryBioMed
Latest Information Update: 10 Jun 2016
At a glance
- Originator DiscoveryBioMed
- Developer DiscoveryBioMed; University of Maryland School of Medicine
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autosomal dominant polycystic kidney disease